Table of Contents
Chapter 1. Research-grade Proteins Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Host Cell Segment
1.2.3. End-use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Research-grade Proteins Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Research-grade Proteins Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Increasing use of recombinant proteins in research activities
3.3.2. Growing research activities for drug discovery and precision medicine
3.3.3. Rising adoption of biologics & biosimilars
3.4. Market Restraint Analysis
3.4.1. Regulatory and safety concerns regarding protein production
3.4.2. Dearth of skilled personnel and expertise
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Research-grade Proteins Market: Product Movement Analysis
4.2. Cytokines & Growth Factors
4.2.1. Cytokines & Growth Factors Market, 2018 – 2030 (USD Million)
4.2.2. Interferons (IFNs)
4.2.2.1. Interferons (IFNs) Market, 2018 – 2030 (USD Million)
4.2.3. Interleukins (ILs)
4.2.3.1. Interleukins (ILs) Market, 2018 – 2030 (USD Million)
4.2.4. Others
4.2.4.1. Others Market, 2018 – 2030 (USD Million)
4.3. Antibodies
4.3.1. Antibodies, 2018 – 2030 (USD Million)
4.4. Immune Checkpoint Proteins
4.4.1. Immune Checkpoint Proteins Market, 2018 – 2030 (USD Million)
4.5. Virus Antigens
4.5.1. Virus Antigens Market, 2018 – 2030 (USD Million)
4.6. Enzymes
4.6.1. Enzymes Market, 2018 – 2030 (USD Million)
4.6.2. Kinases
4.6.2.1. Kinases Market, 2018 – 2030 (USD Million)
4.6.3. Metabolic Enzymes
4.6.3.1. Metabolic Enzymes Market, 2018 – 2030 (USD Million)
4.6.4. Others
4.6.4.1. Others Market, 2018 – 2030 (USD Million)
4.7. Recombinant Regulatory Proteins
4.7.1. Recombinant Regulatory Proteins Market, 2018 – 2030 (USD Million)
4.8. Hormones
4.8.1. Hormones Market, 2018 – 2030 (USD Million)
4.9. Others
4.9.1. Others Market, 2018 – 2030 (USD Million)
Chapter 5. Host Cell Business Analysis
5.1. Research-grade Proteins Market: Host Cell Movement Analysis
5.2. Mammalian Cells
5.2.1. Mammalian Cells Market, 2018 – 2030 (USD Million)
5.3. Bacterial Cells
5.3.1. Bacterial Cells Market, 2018 – 2030 (USD Million)
5.4. Yeast & Fungi
5.4.1. Yeast & Fungi Market, 2018 – 2030 (USD Million)
5.5. Insect Cells
5.5.1. Insect Cells Market, 2018 – 2030 (USD Million)
5.6. Others
5.6.1. Others Market, 2018 – 2030 (USD Million)
Chapter 6. End-use Business Analysis
6.1. Research-grade Proteins Market: End-use Movement Analysis
6.2. Pharmaceutical & Biotechnology Companies
6.2.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
6.3. Academic & Research Institutes
6.3.1. Academic & Research Institutes Market, 2018 – 2030 (USD Million)
6.4. Others
6.4.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Scenario
7.2.2.4. U.S. Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Scenario
7.2.3.4. Canada Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Scenario
7.3.2.4. UK Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Scenario
7.3.3.4. Germany Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.4. Spain
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Scenario
7.3.4.4. Spain Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Scenario
7.3.5.4. France Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Scenario
7.3.6.4. Italy Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Scenario
7.3.7.4. Denmark Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Scenario
7.3.8.4. Sweden Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Scenario
7.3.9.4. Norway Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia-Pacific Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Japan Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. China Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Scenario
7.4.4.4. India Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Scenario
7.4.5.4. South Korea Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Scenario
7.4.6.4. Thailand Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Scenario
7.4.7.4. Australia Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Brazil Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Mexico Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Argentina Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. South Africa Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Saudi Arabia Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. UAE Research-grade Proteins Market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Kuwait Research-grade Proteins Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share/Position Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc.
8.4.1.1. Company Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Abcam Plc
8.4.2.1. Company Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Miltenyi Biotec
8.4.3.1. Company Overview
8.4.3.2. Product Benchmarking
8.4.3.3. Strategic Initiatives
8.4.4. GenScript
8.4.4.1. Company Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Bio-Techne
8.4.5.1. Company Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Proteintech Group, Inc.
8.4.6.1. Company Overview
8.4.6.2. Product Benchmarking
8.4.6.3. Strategic Initiatives
8.4.7. ACROBiosystems
8.4.7.1. Company Overview
8.4.7.2. Product Benchmarking
8.4.7.3. Strategic Initiatives
8.4.8. Sino Biological, Inc.
8.4.8.1. Company Overview
8.4.8.2. Product Benchmarking
8.4.8.3. Strategic Initiatives
8.4.9. Prospec-Tany Technogene Ltd.
8.4.9.1. Company Overview
8.4.9.2. Product Benchmarking
8.4.9.3. Strategic Initiatives
8.4.10. New England Biolabs
8.4.10.1. Company Overview
8.4.10.2. Product Benchmarking
8.4.10.3. Strategic Initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer